Effect of a Russian-backbone live-attenuated influenza vaccine with an updated pandemic H1N1 strain on shedding and immunogenicity among children in The Gambia: an open-label, observational, phase 4 study. by Lindsey, Benjamin B et al.
LSHTM Research Online
Lindsey, Benjamin B; Jagne, Ya Jankey; Armitage, Edwin P; Singanayagam, Anika; Sallah, Hadĳatou
J; Drammeh, Sainabou; Senghore, Elina; Mohammed, Nuredin I; Jeffries, David; Höschler, Katja; +7
more... Tregoning, John S; Meĳer, Adam; Clarke, Ed; Dong, Tao; Barclay, Wendy; Kampmann,
Beate; de Silva, Thushan I; (2019) Effect of a Russian-backbone live-attenuated influenza vaccine with
an updated pandemic H1N1 strain on shedding and immunogenicity among children in The Gambia:
an open-label, observational, phase 4 study. The Lancet. Respiratory medicine. ISSN 2213-2600 DOI:
https://doi.org/10.1016/s2213-2600(19)30086-4
Downloaded from: http://researchonline.lshtm.ac.uk/4653673/
DOI: https://doi.org/10.1016/s2213-2600(19)30086-4
Usage Guidelines:
Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively
contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
https://researchonline.lshtm.ac.uk
www.thelancet.com/respiratory   Published online June 21, 2019   http://dx.doi.org/10.1016/S2213-2600(19)30086-4 1
Articles
Lancet Respir Med 2019
Published Online 
June 21, 2019 
http://dx.doi.org/10.1016/
S2213-2600(19)30086-4
See Online/Comment 
http://dx.doi.org/10.1016/ 
S2213-2600(19)30145-6
*Contributed equally
Vaccines and Immunity Theme, 
Medical Research Council Unit 
The Gambia at the London 
School of Hygiene & Tropical 
Medicine, Banjul, The Gambia 
(B B Lindsey MBBS, 
Y J Jagne MSc, 
E P Armitage BMBS, 
H J Sallah BSc, S Drammeh BSc, 
E Senghore BSc, 
N I Mohammed PhD, 
D Jeffries PhD, E Clarke PhD, 
Prof B Kampmann PhD, 
T I de Silva PhD); Department of 
Medicine, Imperial College 
London, London, UK 
(B B Lindsey, 
A Singanayagam MRCP, 
J S Tregoning PhD, 
Prof W Barclay PhD, T I de Silva); 
Virus Reference Department, 
Reference Microbiology 
Services, Public Health 
England, London, UK 
(K Höschler PhD); Centre for 
Infectious Disease Research, 
Diagnostics and Laboratory 
Surveillance, National Institute 
for Public Health and the 
Environment, Bilthoven, 
Netherlands (A Meijer PhD); 
Medical Research Council 
Human Immunology Unit, 
Weatherall Institute of 
Molecular Medicine, and 
Chinese Academy of Medical 
Science—Oxford Institute, 
Nuffield Department of 
Medicine, Oxford University, 
Oxford, UK (Prof T Dong DPhil); 
The Vaccine Centre, London 
School of Hygiene & Tropical 
Medicine, Faculty of Infectious 
and Tropical Diseases, London,
Introduction
Live attenuated influenza vaccine (LAIV) has been highly 
efficacious against prepandemic seasonal H1N1 viruses 
in children, with a meta-analysis1 estimating a pooled 
efficacy of 85% from several randomised controlled 
trials. However, concerns have been expressed about 
protection against pandemic H1N1 (pH1N1) influenza 
using LAIV. Since 2009, when pH1N1 viruses have 
circulated as the main seasonal H1N1 strain, vaccine 
effectiveness of the Ann Arbor-backbone LAIV against 
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Summary
Background The efficacy and effectiveness of the pandemic H1N1 (pH1N1) component in live attenuated influenza 
vaccine (LAIV) is poor. The reasons for this paucity are unclear but could be due to impaired replicative fitness of 
pH1N1 A/California/07/2009-like (Cal09) strains. We assessed whether an updated pH1N1 strain in the Russian-
backbone trivalent LAIV resulted in greater shedding and immunogenicity compared with LAIV with Cal09.
Methods We did an open-label, prospective, observational, phase 4 study in Sukuta, a periurban area in The Gambia. 
We enrolled children aged 24–59 months who were clinically well. Children received one dose of the WHO pre-
qualified Russian-backbone trivalent LAIV containing either A/17/California/2009/38 (Cal09) or A/17/New 
York/15/5364 (NY15) based on their year of enrolment. Primary outcomes were the percentage of children with LAIV 
strain shedding at day 2 and day 7, haemagglutinin inhibition seroconversion, and an increase in influenza 
haemagglutinin-specific IgA and T-cell responses at day 21 after LAIV. This study is nested within a randomised 
controlled trial investigating LAIV–microbiome interactions (NCT02972957).
Findings Between Feb 8, 2017, and April 12, 2017, 118 children were enrolled and received one dose of the Cal09 
LAIV from 2016–17. Between Jan 15, 2018, and March 28, 2018, a separate cohort of 135 children were enrolled and 
received one dose of the NY15 LAIV from 2017–18, of whom 126 children completed the study. Cal09 showed 
impaired pH1N1 nasopharyngeal shedding (16 of 118 children [14%, 95% CI 8·0–21·1] with shedding at day 2 after 
administration of LAIV) compared with H3N2 (54 of 118 [46%, 36·6–55·2]; p<0·0001) and influenza B (95 of 118 
[81%, 72·2–87·2]; p<0·0001), along with suboptimal serum antibody (seroconversion in six of 118 [5%, 1·9–10·7]) 
and T-cell responses (CD4+ interferon γ-positive and/or CD4+ interleukin 2-positive responses in 45 of 111 [41%, 
31·3–50·3]). After the switch to NY15, a significant increase in pH1N1 shedding was seen (80 of 126 children [63%, 
95% CI 54·4–71·9]; p<0·0001 compared with Cal09), along with improvements in seroconversion (24 of 126 
[19%, 13·2–26·8]; p=0·011) and influenza-specific CD4+ T-cell responses (73 of 111 [66%, 60·0–75·6; p=0·00028]). 
The improvement in pH1N1 seroconversion with NY15 was even greater in children who were seronegative at 
baseline (24 of 64 children [38%, 95% CI 26·7–49·8] vs six of 79 children with Cal09 [8%, 2·8–15·8]; p<0·0001). 
Persistent shedding to day 7 was independently associated with both seroconversion (odds ratio 12·69, 95% CI 
4·1–43·6; p<0·0001) and CD4+ T-cell responses (odds ratio 7·83, 95% CI 2·99–23·5; p<0·0001) by multivariable 
logistic regression.
Interpretation The pH1N1 component switch that took place between 2016 and 2018 might have overcome the poor 
efficacy and effectiveness reported with previous LAIV formulations. LAIV effectiveness against pH1N1 should, 
therefore, improve in upcoming influenza seasons. Our data highlight the importance of assessing replicative fitness, 
in addition to antigenicity, when selecting annual LAIV components.
Funding The Wellcome Trust.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 
license.
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pH1N1 in the USA has been low, ranging from –21% in 
2015–16 to 17% in 2013–14.2 This reduction in 
effectiveness resulted in the Advisory Committee on 
Immunisation Practices removing their recommendation 
for LAIV use in 2016.3 
A randomised controlled trial of Russian-backbone 
LAIV (Nasovac-S; Serum Institute of India Pvt, Pune, 
India) among children aged 2–5 years in Senegal did not 
show efficacy (0·0%, 95% CI –26·4 to 20·9) in 2013, 
when pH1N1 was the predominant circulating vaccine-
matched virus.4 Both LAIV formulations in these studies 
contained haemagglutinin and neuraminidase from 
pH1N1 A/California/07/2009-like (Cal09) viruses. It is 
unclear why protection conferred by the pH1N1 
component in LAIV has been suboptimal. Potential 
reasons include pre-existing immunity, poor viral 
replicative fitness, or competition from other co-
formulated strains—all limiting pH1N1 take and 
immunogenicity.3
The Russian-backbone LAIV (Nasovac-S) was granted a 
WHO prequalification certificate in 2015, opening up the 
potential for use in low-income and middle-income 
countries. The findings in Senegal with this vaccine are 
especially pertinent because the burden of influenza in 
Africa is high; influenza-related admissions to hospital 
in children younger than 5 years are approximately 
threefold higher than in Europe.5 Superior efficacy of 
LAIV over inactivated influenza vaccine in young 
children (predominantly in high-income settings),1 
needle-free delivery, and lower manufacturing costs 
make LAIV an attractive option to tackle this burden in 
Africa.3 However, few LAIV studies have been done in 
African cohorts and no published immunogenicity data 
are available from African children to date.6 In particular, 
the absence of immunological endpoints from the 
randomised controlled trial in Senegal makes it difficult 
to understand the reasons for the lack of efficacy 
recorded.4
In 2017–18, the pH1N1 Cal09 strain (A/17/
California/2009/38) was updated according to WHO 
recommendations to an A/Michigan/45/2015-like strain 
(A/17/New York/15/5364 [NY15]), following antigenic 
drift. This first-ever recommended update to pH1N1 
provided a unique opportunity to compare replicative 
ability and immuno genicity of these two pH1N1 strains. 
To understand how differences in strain shedding and 
immunogenicity might account for the findings of the 
Senegal trial, we compared one cohort of influenza 
vaccine-naive Gambian children vaccinated with the 
Russian-backbone Cal09 LAIV formulation from 2016–17 
with a second cohort vaccinated with the NY15 LAIV 
formulation from 2017–18.
Research in context
Evidence before this study
We searched Embase, MEDLINE, Global health, and Web of 
Science databases up to May 9, 2018, with the terms: 
(“influenza” OR “flu”) AND (“vaccin*” OR “immuni#ation” 
OR “Influenza Vaccines [Subject heading]”) AND (“effic*” OR 
“effect*” OR “immune*” OR “respons*” OR “protect*”) AND 
(“Africa” OR “Africa [Subject heading]” OR each African country 
[defined by the UN]). This search strategy identified no live 
attenuated influenza vaccine (LAIV) immunogenicity studies 
and only two LAIV efficacy studies in African children. 
The first study was of the Ann-Arbor LAIV in 2001–02, when 
pre-pandemic H1N1 was circulating. This study was a 
multicentre randomised placebo-controlled trial that included 
277 children aged 6–36 months from South Africa. The efficacy 
of LAIV in this subset of children was 87% (95% CI 64–95). 
The second study was a single-centre, randomised, 
placebo-controlled trial of Russian-backbone LAIV in children 
aged 2–5 years in Senegal. The study was done in 2013 and, 
therefore, included pandemic H1N1 (pH1N1). The efficacy 
against vaccine-matched isolates was –6·1% (95% CI 
–50·0 to 25·0), and pH1N1 was the predominant circulating 
strain. In the 2017–18 season, the pH1N1 component in LAIV 
was updated for the first time in both the Ann Arbor and 
Russian-backbone LAIVs, with A/Michigan/45/2015-like 
strains. No studies have been published about whether this 
change has affected the shedding and immunogenicity of 
pH1N1 in LAIV.
Added value of this study
Our findings show that A/17/California/2009/38 pH1N1 strain 
shedding and immunogenicity is less than that of H3N2 and 
influenza B in the Russian-backbone LAIV, providing an 
explanation for the lack of efficacy seen in the randomised 
controlled trial in Senegal. Our data suggest this observation is 
not attributable to reduced pH1N1 vaccine take secondary to 
pre-existing immune responses. Our findings show for the 
first time that updating the Russian-backbone LAIV pH1N1 
component has resulted in a vaccine with significantly greater 
nasopharyngeal shedding, seroconversion, and 
influenza-specific T-cell induction to pH1N1. We are able to 
model this difference in replicative ability of old and new 
pH1N1 LAIV components in vitro.
Implications of all the available evidence
Impaired replicative ability of pH1N1 components in LAIV 
might have caused recent low efficacy and effectiveness of 
LAIV. An improvement in protection against pH1N1 can be 
expected in the future. These data highlight the importance of 
assessing viral replicative fitness in addition to antigenicity 
when selecting vaccine formulations. Studies are needed to 
ascertain whether improved shedding and immunogenicity 
translates into improved efficacy and effectiveness. Further 
research is needed to understand the genetic factors that 
underlie these phenotypes in vaccine strains to design more 
rational choices of vaccine antigens for LAIV.
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Methods
Study design and participants
We did an open-label, prospective, observational, phase 4 
immunogenicity study in Sukuta, a periurban area in 
The Gambia. Our study is nested within a larger 
randomised trial comparing microbiome changes in 
children assigned LAIV with changes in unvaccinated 
children (NCT02972957; appendix pp 3, 4). Data in our 
study are from all children enrolled in the randomised 
trial who were given LAIV. After community sensitis-
ation, parents expressing an interest in the randomised 
study were invited for consent discussions. Eligible 
children had to be aged 24–59 months and clinically 
well, with no history of respiratory illness within the past 
14 days (appendix p 2).
This study was approved by The Gambia Government 
and UK Medical Research Council (MRC) joint ethics 
committee and the Medicines Control Agency of The 
Gambia, and it was done according to International 
Conference on Harmonisation Good Clinical Practice 
standards. A parent provided written or thumbprinted 
informed consent for their child or children to 
participate. If parents were not English literate, an 
impartial witness was present throughout the informed 
consent discussion undertaken in a local language, who 
signed to confirm completeness of the consent provided.
Procedures
When LAIV was updated in 2017–18, haemagglutinin 
and neuraminidase from pH1N1 Cal09 were replaced 
with those from NY15, whereas identical H3N2 (A/17/
Hong Kong/2014/8296) and B/Vic (B/Texas/02/2013 
[Victoria lineage]) strains were used. Vaccine titres per 
dose (50% egg infectious dose equivalents [EID50eq] 
per mL) were 1 × 10⁸·⁰ for pH1N1, 1 × 10⁷·⁵ for H3N2, 
1 × 10⁷·² for B/Vic in the 2016–17 LAIV and 1 × 10⁷·⁷ for 
pH1N1, 1 × 10⁷·⁶ for H3N2, 1 × 10⁷·³ for B/Vic in the 
2017–18 LAIV.
The study was done outside the peak influenza 
transmission season (June to October) based on sur veill-
ance data from Senegal and unpublished data from 
studies in The Gambia.7 Children received one dose of 
intranasal trivalent Russian-backbone LAIV (Nasovac-S; 
northern hemisphere formulation) in either 2017 (the 
Cal09 strain from 2016–17) or 2018 (the NY15 strain from 
2017–18 formulation). Children received the vaccine 
formulation that corresponded with their year of 
enrolment.
Nasopharyngeal swabs were taken before vaccination 
(day 0), on day 2, and on day 7 using flocked swabs 
(FLOQSwabs; Copan, Murrieta, CA, USA). We obtained 
buccal cavity oral fluid with swabs (Oracol Plus; Malvern 
Medical Development, Worcester, UK) on day 0 and 
day 21. Whole blood samples were obtained for flow 
cytometry and serum separation on day 0 and day 21. We 
chose day 21 to measure vaccine response, in line with 
previous work.8–10 Nasopharyngeal swabs, oral fluid, and 
serum samples were stored at –70°C before further 
processing.
Haemagglutinin inhibition assays were done according 
to standard methods,11 using vaccine haemagglutinin-
matched and neuraminidase-matched viruses. Sero-
conversion was defined as a fourfold or greater titre 
increase (to ≥1:40) from day 0 to day 21. Total and 
influenza haemagglutinin-specific IgA in oral fluid was 
detected using a previously described ELISA,12 using 
recombinant vaccine-matched haemagglutinin. Samples 
were assayed at dilutions ranging from 1:1000 to 1:20000 
for total IgA and from undiluted to 1:16 for influenza-
specific IgA, and samples were quantified using an IgA 
standard curve. Undiluted samples with influenza-
specific IgA below the limit of quantitation (LOQ) were 
assigned LOQ values. We calculated the fold change in 
the proportion of influenza-specific IgA to total IgA from 
day 0 to day 21. A twofold increase was considered a 
significant response.13
T-cell responses were quantified by stimulating fresh 
whole blood (200 µL) on the day of collection for 18 h 
with overlapping 15–18-mer peptide pools (2 µg/mL) 
covering vaccine-matched whole haemagglutinin, 
matrix and nucleoprotein, and co-stimulatory anti-
bodies (antiCD28 and antiCD49; BD Biosciences, 
Franklin Lakes, NJ, USA). Influenza B responses were 
measured in 2018 only. We did intracellular cytokine 
staining for interferon (IFN)γ and interleukin (IL)2 and 
analysed cells with a flow cytometer (LSR Fortessa; 
BD Biosciences; appendix pp 5, 6).14 Responses in 
negative controls (antiCD28 and antiCD49) were 
subtracted from peptide-stimulated conditions before 
further analysis; negative values were set to zero. To 
avoid systematic bias in adjusting for negative values 
alone, we set a threshold (based on the distribution of 
negative values; appendix p 7) below which all positive 
values were also considered a non-response, as 
described previously.14,15 In analyses calculating the fold 
change from day 0 to day 21, null responses were 
assigned a value halfway between zero and this 
threshold. A twofold increase after LAIV was considered 
a sig nifi cant response.
Vaccine shedding from nasopharyngeal swabs was 
assessed with monoplex reverse-transcriptase PCR 
(RT-PCR) using haemagglutinin-specific primers and 
probes (appendix p 8). In 2018, fully quantitative 
RT-PCR results were obtained by inclusion of a standard 
curve with known vaccine titres (log10EID50eq per mL; 
appendix p 9). RT-PCR assays with primers and probes 
mapping to internal genes were used to distinguish 
LAIV from seasonal influenza viruses (appendix p 8).16 
Despite optimisation of assay conditions, maximum 
LAIV dilutions detected by LAIV-specific RT-PCR were 
at least one log10 lower than those detected by 
haemagglutinin-specific RT-PCR (appendix p 10). 
Therefore, only samples with cycle threshold (ct) values 
of 30 or lower in seasonal influenza assays were tested 
See Online for appendix
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with LAIV-specific assays, with 100% confirmed as LAIV 
strains.
Primary human nasal epithelial cell cultures (MucilAir; 
Epithelix Sàrl, Geneva, Switzerland) were used for in vitro 
viral replication experiments. Madin-Darby Canine 
Kidney (MDCK) cells (ATCC, Manassas, VA, USA) and 
MDCK-SIAT cells (WHO Collaborating Centre for 
Reference and Research on Influenza, London, UK) were 
maintained at 37°C with 5% CO2 in Dulbecco’s modified 
Eagle’s Medium (DMEM; Gibco-Life Technologies, 
Waltham, MA, USA) supplemented with 10% fetal bovine 
serum, 1% penicillin–streptomycin, and 1% non-essential 
amino acids. We also added 1 mg/mL G418 (Gibco-Life 
Technologies) for MDCK-SIAT cells. Viral stocks of 
Nasovac-S monovalent forms were titrated by plaque assay 
at 32°C on MDCK cells (for pH1N1 and influenza B) or 
MDCK-SIAT cells (for H3N2). Apical surfaces of human 
nasal epithelial cells were inoculated with each monovalent 
virus (multiplicity of infection 0·01 plaque-forming units 
per cell) for 1 h at 32°C and 5% CO2 in triplicate. The 
inoculum was removed and the apical surface of the 
human nasal epithelial cells was washed with DMEM 
before incubation at 32°C. At indicated timepoints (days 
1–6 after inoculation), DMEM was added to the human 
nasal epithelial cells and incubated for 30 min, then it was 
removed and stored; the stored DMEM—containing 
virions from the epithelial cell cultures—was titrated by 
plaque assay. Experiments were done on two separate 
occasions using cells from different donors.
To assess the acid stability of pH1N1 strains, Cal09 or 
NY15 were mixed with pH-adjusted MES (2-[N-morpholino]
ethanesulphonic acid) buffer (100 mmol/L MES, 150 mol/L 
sodium chloride, 0·9 mol/L calcium chloride, 0·5 mol/L 
magnesium chloride) in triplicate (1:10 dilution) and the 
mixture was incubated for 15 min at room temperature. 
The buffer was inactivated with DMEM and infectious 
virus was titrated by plaque assay.
Outcomes
Primary shedding and immunogenicity outcomes were 
the percentage of children with LAIV strain shedding 
at day 2 and day 7, haemagglutinin inhibition sero-
conversion, and an increase in influenza haemagglutinin-
specific IgA and T-cell responses at day 21 after LAIV.
Statistical analysis
The sample size calculation was based on LAIV micro-
biome endpoints not presented here (appendix p 3). 
Differences in unpaired proportions (shedding, sero-
conversion, IgA responses, and T-cell responses) between 
years (2017 and 2018) were assessed with either the χ² test 
or Fisher’s exact test. Differences in continuous variables 
(ct value, log10EID50eq per mL, and geometric mean fold 
change in haemagglutinin inhibition) between years (2017 
and 2018) or serostatus (positive or negative) were assessed 
with either the unpaired t test or Mann-Whitney U test. 
Differences in viral load (log10EID50eq per mL) between 
strains (NY15, H3N2, and influenza B) within the same 
visit (paired data) were assessed with the Friedman test 
(with Dunn’s post-test for multi ple com parisons). Pairwise 
viral load correlations were assessed using Spearman’s 
rank-order correlation (rs). Correlation coefficients 
were interpreted as low (rs=0·30–0·49), moderate 
(rs=0·50–0·69), high (rs=0·70–0·89), or very high 
(rs=0·90–1·00). The Wilcoxon signed-rank test was used to 
compare T-cell responses before and after vaccination. 
Separate logistic regression analyses were done for 
dependent variables (shedding, sero conversion, T-cell 
responses, and IgA responses). Independent variables 
were selected for multivariable logistic re gression models 
if biologically relevant and the p value from univariable 
regression was less than 0·2. Each multivariable logistic 
regression model always included year, age, and sex as 
potential confounders. Viral loads were ascertained from 
standard curves using Python version 3.6 (SciPy package). 
In vitro viral replication was quantified using the area 
under the curve function in GraphPad Prism 5.0d 
(GraphPad Software, San Diego, CA, USA) and compared 
between NY15 and Cal09 strains using an unpaired t test. 
The proportion of monofunctional and dual-functional 
T-cell responses were estimated using Boolean gating on 
FlowJo 10.4 (FlowJo LLC, Ashland, OR, USA) and 
statistical significance between timepoints tested with the 
Permutation test in SPICE (version 6.0).15 Proportions are 
displayed with 95% CIs. All tests were two-sided at the 
5% signifi cance level and were Bonferroni-adjusted 
for multiple comparisons within each set of analyses. 
Statistical analyses were done using R version 3.5.1, Stata 
release 12 (StataCorp, College Station, TX, USA), and 
GraphPad Prism 5.0d.
Role of the funding source
The funder had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
BBL, TIdS, EPA, YJJ, NIM, DJ, KH, and AS had access to 
raw data. The corresponding author had full access to all 
data in the study and had final responsibility for the 
decision to submit for publication.
Results
Between Feb 8, 2017, and April 12, 2017, 118 children 
were enrolled and received one dose of the 2016–17 
northern hemisphere formulation LAIV (Cal09 pH1N1; 
figure 1A). Between Jan 15, 2018, and March 28, 2018, 
a separate cohort of 135 children were enrolled and 
received one dose of the 2017–18 northern hemisphere 
formulation LAIV (NY15 pH1N1; figure 1B). 118 children 
in 2017 and 126 children in 2018 completed the study. All 
study visits were within protocol-defined windows 
(+1 day for day 2 visit, +7 days for day 7 visits, and +7 days 
for day 21 visits). In the 2017 cohort, 118 (100%) of 
118 day 2 visits were 2 days after LAIV, 115 (97%) of 
118 day 7 visits were 7 days after LAIV (three visits were 
8 days, 12 days, and 14 days after LAIV), and 112 (95%) of 
For more on SciPy see 
http://www.scipy.org/
For more on R see 
https://www.r-project.org/
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118 day 21 visits were 21 days after LAIV (five visits were 
22 days after LAIV and one was 25 days after LAIV). In 
the 2018 cohort, 122 (97%) of 126 day 2 visits were 2 days 
after LAIV (four visits were 3 days after LAIV), 119 (94%) 
of 126 day 7 visits were 7 days after LAIV (seven visits 
were 8 days after LAIV), and 117 (93%) of 126 day 21 visits 
were 21 days after LAIV (eight visits were 22 days after 
LAIV and one visit was 26 days after LAIV). Baseline 
demographics did not differ significantly between the 
two cohorts with the exception of baseline haemagglutinin 
inhibition titres (table).
No influenza strains were detected from naso pharyn-
geal swabs taken immediately before vaccination in 
any children. After administration of the 2016–17 LAIV, 
pH1N1 Cal09 shedding was seen in significantly 
fewer children (16 of 118 [14%, 95% CI 8·0–21·1]) at 
day 2 compared with H3N2 (54 of 118 [46%, 36·6–55·2]; 
p<0·0001) and B/Vic (95 of 118 [81%, 72·2–87·2]; 
p<0·0001; figure 2). No pH1N1 Cal09 shedding was 
recorded at day 7 with the 2016–17 LAIV, with H3N2 
shedding noted in 21 of 118 children (18%, 95% CI 
11·4–25·9) and B/Vic shedding in 70 of 118 children 
(59%, 49·9–68·3). Administration of the 2017–18 LAIV 
resulted in significantly more children shedding pH1N1 
NY15 at day 2 (80 of 126 [63%, 95% CI 54·4–71·9]; 
p<0·0001 compared with pH1N1 Cal09; figure 2A), with 
shedding of H3N2 seen in 82 of 126 children 
(65%, 95% CI 56·1–73·4) and shedding of B/Vic reported 
in 91 of 126 children (72%, 63·5–79·8). Shedding of 
pH1N1 NY15 was detected at day 7 with the 2017–18 LAIV 
(65 of 126 children [52%, 42·5–60·6]), with shedding of 
H3N2 recorded in 40 of 126 children (32%, 95% CI 
23·7–40·6) and shedding of B/Vic noted in 60 of 
126 children (48%, 38·7–56·7).
Significantly higher pH1N1 nasopharyngeal viral loads 
(lower ct values) were also seen with the 2017–18 LAIV 
compared with the 2016–17 LAIV at day 2 (p=0·0026; 
figure 2B). Quantitative RT-PCR data showed that pH1N1 
Figure 1: Study profile
Overview of participants who received (A) the 2016–17 northern hemisphere Russian-backbone LAIV formulation and (B) the 2017–18 northern hemisphere Russian-backbone LAIV formulation. 
LAIV=live attenuated influenza vaccine. pH1N1=pandemic H1N1. HAI=haemagglutinin inhibition. *The study was nested within a larger randomised controlled trial (NCT02972957; appendix pp 3,4). 
†Sparse cell populations seen on flow cytometry. ‡Total IgA not detected in sample. §No pH1N1 data for one sample in 2016–17 cohort and no pH1N1 data for four samples and H3N2 data for 
three samples in 2017–18 cohort because of inadequate sample volume.
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 4 ineligible
 1 severe weight-for-height malnutrition
 3 acute respiratory illness in past 14 days
60 randomised to unvaccinated arm of parent 
 study*
A B2016–17 northern hemisphere formulation cohort 2017–18 northern hemisphere formulation cohort
118 completed study
118 participants enrolled and given LAIV*
182 assessed for eligibility
118 included in 
         shedding 
 analysis
118 included in 
         serum HAI 
 analysis
118 included in 
         mucosal IgA 
         analysis§
109 included in 
         T-cell analysis
15 poor
 sample
 quality†
1 poor
 sample
 quality‡
 9 ineligible
 7 acute respiratory illness in past 14 days
 1 other acute illness
 1 age older than 59 months
50 randomised to unvaccinated arm of parent 
 study*
 2 enrolled but missed study visit and withdrew
 consent
126 completed study
135 participants enrolled and given LAIV*
196 assessed for eligibility
126 included in 
         shedding 
 analysis
126 included in 
         serum HAI 
         analysis
125 included in 
         mucosal IgA 
         analysis§
111 included in 
         T-cell analysis
9 missed study visits and withdrew consent
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NY15 viral loads from the 2017–18 LAIV were significantly 
higher than H3N2 (p<0·0001) and B/Vic (p=0·0028) at 
day 2 (figure 2C). To investigate whether the improved 
replication of pH1N1 with the 2017–18 LAIV resulted in 
greater competition with H3N2 and B/Vic and, therefore, 
lower viral loads of these strains, viral loads were 
compared in co-shedders of each strain. No significant 
negative effect on H3N2 and B/Vic replication was 
reported, with a significant positive correlation between 
pH1N1 and H3N2 shedding noted at day 2 (low 
correlation, rs=0·40; p=0·0012) and day 7 (moderate 
correlation, rs=0·51; p=0·0032; appendix p 11).
To ascertain whether pre-existing adaptive immunity 
accounted for poor pH1N1 Cal09 shedding, univariable 
logistic regression was done to calculate the predicted 
probability of shedding at each baseline haemagglutinin 
inhibition titre (figure 3), adjusting for year in the H3N2 
and B/Vic models. Although an inverse relation was 
evident for H3N2 (figure 3C) and B/Vic (figure 3D) 
between baseline haemagglutinin inhibition titre and 
shedding, this relation was not evident for Cal09 
(figure 3A), for which low shedding was predicted even 
2016–17 LAIV 
(n=118)
2017–18 LAIV 
(n=126)
p value
Age (months) 35·1 (28·3–44·9) 35·3 (28·0–40·5) 0·44
Sex ·· ·· 0·61
Female 57 (48%) 56 (44%) ··
Male 61 (52%) 70 (56%) ··
Height (cm) 92·9 (7·4) 91·8 (6·3) 0·23
Weight (kg) 12·9 (2·1) 12·6 (1·7) 0·30
Weight-for-height malnutrition* ·· ·· 0·93
None 76 (64%) 82 (65%) ··
Mild 33 (28%) 36 (29%) ··
Moderate 9 (8%) 8 (6%) ··
Tribe ·· ·· 0·27
Mandinka 96 (81%) 99 (79%) ··
Wolof 5 (4%) 7 (6%) ··
Fula 3 (3%) 5 (4%) ··
Jola 6 (5%) 4 (3%) ··
Serehule 2 (2%) 5 (4%) ··
Serere 5 (4%) 1 (1%) ··
Other 1 (1%) 5 (4%) ··
History of ever being admitted to hospital 
with a respiratory infection
6 (5%) 3 (2%) 0·32
History of more than one respiratory infection 
needing medication in the past year
8 (7%) 13 (10%) 0·37
Age when stopped breastfeeding (months) 20 (18–24) 20 (18–24)† 0·80
Baseline seropositive (haemagglutinin inhibition titre ≥1:10)
pH1N1‡ 39 (33%) 62 (49%) 0·013
H3N2 90 (76%) 70 (56%) 0·00070
B/Vic 25 (21%) 54 (43%) 0·00040
Haemagglutinin inhibition titre in children seropositive at baseline
pH1N1‡ 160 (80–160) 226 (160–320) 0·00050
H3N2 160 (80–160) 160 (80–320) 0·16
B/Vic 160 (80–226·3) 226 (160–320) 0·015
Data are n (%), median (IQR), or mean (SD). pH1N1=pandemic H1N1. *Malnutrition was categorised based on 
weight-for-height SD (Z score): none (>–1), mild (–2 to <–1), moderate (–3 to <–2). Children with severe malnutrition 
(weight-for-height SD <–3) were excluded. †Missing data for two children. ‡pH1N1 virus used for serum 
haemagglutinin inhibition assays was changed for the cohort given 2017–18 LAIV to reflect the update from 
Cal09 to NY15.
Table: Demographic characteristics and baseline influenza serological data
Figure 2: Shedding of strains in the nasopharynx after vaccination
(A) Percentage of children shedding vaccine virus with 2016–17 LAIV formulation 
compared with the 2017–18 LAIV formulation, at day 2 and day 7. Error bars 
represent the upper 95% CI. (B) Viral load in the nasopharynx is indicated by 
ct values from RT-PCR. Red bars indicate median ct values. Lower ct values 
indicate higher viral loads. (C) Quantitative RT-PCR viral load in children from the 
2018 cohort for each strain. Red bars indicate median values. p values are 
Bonferroni-adjusted for multiplicity within each group of analyses. LAIV=live 
attenuated influenza vaccine. pH1N1=pandemic H1N1. H3N2=A/17/Hong 
Kong/2014/8296. B/Vic=B/Texas/02/2013 (Victoria lineage). ct=cycle threshold. 
RT-PCR=reverse-transcriptase PCR. EID50eq=50% egg infectious dose equivalents.
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Figure 3: Effect of baseline 
serum antibody on LAIV 
strain shedding in the 
nasopharynx and replicative 
ability of viruses in primary 
epithelial cell cultures
(A–D) Predicted probability 
from logistic regression of 
vaccine strain shedding at 
day 2 after LAIV at a given 
baseline serum HAI titre to 
each matched strain. Dots 
show predicted proportions 
and shaded areas show 
95% CIs. Data shown for Cal09 
pH1N1 (A), NY15 pH1N1 (B), 
H3N2 (C), and B/Vic (D). Upper 
limit is based on maximum 
observed HAI titre in the 
dataset. When data from 2017 
and 2018 were combined for 
H3N2 and B/Vic, results were 
adjusted for year (appendix 
p 12). (E) Nasopharyngeal viral 
load at day 2 and day 7 after 
2017–18 LAIV, with 
participants stratified by 
baseline serostatus to vaccine 
haemagglutinin-matched and 
neuraminidase-matched 
influenza strains. Red bars 
indicate median values. 
(F and G) Replication of pH1N1 
(F) or H3N2 and B/Vic (G) 
vaccine strains in primary nasal 
epithelium. Dots denote mean 
values and errors bars the SD. 
In (F), p<0·0001 comparing 
area under the curve. 
(H) Effect of pH on vaccine 
strain growth in vitro. Dots 
denote mean values and errors 
bars the SD. The y axis is a 
logarithmic scale. LAIV=live 
attenuated influenza vaccine. 
HAI=haemagglutinin 
inhibition. pH1N1=pandemic 
H1N1. Cal09=A/17/
California/2009/38. 
NY15=A/17/New 
York/15/5364. 
H3N2=A/17/Hong 
Kong/2014/8296. 
B/Vic=B/Texas/02/2013 
(Victoria lineage). 
EID50eq=50% egg infectious 
dose equivalents. 
PFU=plaque-forming units. 
p values for specific timepoints 
are *p=0·047, †p=0·0019, 
‡p=0·029, §p=0·013, and 
¶p<0·0001.
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in seronegative children. By contrast, NY15 shedding was 
inversely related to the magnitude of the baseline 
haemagglutinin inhibition titre (figure 3B). Logistic 
regression also showed no associations between 
shedding and prevaccination T-cell responses or 
haemagglutinin-specific mucosal IgA responses for 
Cal09 (appendix p 12). Similarly, no association was seen 
between T-cell responses or IgA responses and shedding 
for H3N2 or B/Vic strains, after adjusting for baseline 
haemagglutinin inhibition titre (appendix p 12). 
Figure 4: Immunogenicity to pH1N1 with the 2016–17 and 2017–18 LAIV formulations
p values are Bonferroni-adjusted for multiplicity within each group of analyses. (A) Percentage of children seroconverting to each LAIV strain, comparing 2016–17 and 
2017–18 formulations. Error bars represent the upper 95% CI. (B) Geometric mean fold change in serum haemagglutinin inhibition titre from baseline to day 21, 
comparing children seronegative at baseline given 2016–17 and 2017–18 LAIVs. Dotted line depicts a fold change of four. y axis is a logarithmic scale. (C) Influenza-specific 
CD4+ T-cell responses to vaccine strain-matched pH1 haemagglutinin (Cal09 in 2016–17 or NY15 in 2017–18), H3 haemagglutinin, influenza A matrix and nucleoprotein 
(both matched to LAIV backbone) peptide pools, comparing 2016–17 and 2017–18 LAIVs. Error bars represent the upper 95% CI. (D) Percentage of children with a twofold 
rise in influenza-specific CD4+ T-cell responses at day 21 after 2016–17 and 2017–18 LAIVs. y axis is a logarithmic scale. (E) Percentage of influenza-specific mucosal IgA 
responders given the 2016–17 and 2017–18 LAIVs. Error bars represent the upper 95% CI. pH1N1=pandemic H1N1. LAIV=live attenuated influenza vaccine. 
Cal09=A/17/California/2009/38. NY15=A/17/New York/15/5364. H3N2=A/17/Hong Kong/2014/8296. B/Vic=B/Texas/02/2013 (Victoria lineage). IFNγ=interferon γ.
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Significantly lower nasopharyngeal viral loads were 
recorded at day 2 and day 7 for all three strains in baseline 
seropositive children compared with baseline 
seronegative children who received the 2017–18 LAIV 
formulation (figure 3E), further emphasising the impor-
tance of serum antibody in this process.
In the seronegative population, shedding of pH1N1 
Cal09 at day 2 was reported in ten of 79 children (13%, 
95% CI 7·0–21·8) whereas shedding of pH1N1 NY15 was 
noted in 58 of 64 children (91%, 81·0–95·6; p<0·0001). 
Shedding of H3N2 with the 2016–17 LAIV was seen in 21 
of 28 seronegative children (75·0%, 95% CI 56·6–87·3) 
and with the 2017–18 LAIV, shedding of H3N2 was 
recorded in 46 of 56 seronegative children (82%, 
70·2–90·0; p=0·63). In the same seronegative population, 
shedding of B/Vic with the 2016–17 LAIV was detected in 
78 of 93 children (84%, 95% CI 75·1–90·0) and, with the 
2017–18 LAIV, shedding of B/Vic was recorded in 57 of 
72 children (79%, 68·4–86·9; p=0·57). Comparisons of ct 
values between 2016–17 and 2017–18 LAIV strains in 
seronegative children showed a lower ct value (higher 
viral load) at day 2 with pH1N1 NY15 compared with 
pH1N1 Cal09 (p<0·0001; appendix p 13).
Monovalent vaccine strain replication was tested in 
primary human nasal epithelial cells cultured at an air–
liquid interface to see whether in-vitro kinetics (in the 
absence of adaptive immune responses) reflected Cal09 
and NY15 pH1N1 shedding in children. NY15 replication 
was greater than Cal09 replication (figure 3F), whereas 
H3N2 and B/Vic growth was equivalent (figure 3G). Since 
stability in acidic environments in the upper respiratory 
tract could be important for replicative ability, Cal09 and 
NY15 were quantified after exposure to varying pH levels. 
Greater stability of NY15 was seen in acidic environments 
compared with Cal09 (figure 3H).
The 2016–17 LAIV resulted in significantly fewer 
children sero converting to pH1N1 Cal09 (six of 118 
[5%, 95% CI 1·9–10·7]) compared with H3N2 (26 of 118 
[22%, 14·9–30·6]; p=0·00030) and B/Vic (40 of 118 
[34%, 25·4–43·2]; p<0·0001). A significant increase was 
recorded in pH1N1 NY15 seroconversion with the 2017–18 
LAIV compared with Cal09 (24 of 126 [19%, 95% CI 
13·2–26·8]; p=0·011; figure 4A), with no difference in 
H3N2 (35 of 126 [28%, 20·7–36·2]; p=1·00) or B/Vic (30 
of 126 [24%, 17·2–32·0]; p=0·11). The improved sero-
conversion to pH1N1 with NY15 compared with Cal09 
was especially evident in seronegative children (24 of 64 
[38%, 95% CI 26·7–49·8] vs six of 79 [8%, 2·8–15·8]; 
p<0·0001; figure 4A), with a significant difference 
in geometric mean fold change in haemagglutinin 
inhibition for pH1N1 NY15 in 2017–18 compared with 
pH1N1 Cal09 in 2016–17 (p<0·0001; figure 4B).
Influenza-specific CD4+ IFNγ-positive, CD4+ IL2-
positive, and CD8+ IFNγ-positive T-cell responses were 
detected at baseline and after vaccination. Although the 
magnitude of CD8+ responses was generally higher, 
LAIV-induced responses were pre dominantly CD4+ 
(figures 4C and 4D; appendix pp 14, 15). The 2016–17 LAIV 
did not induce significant pH1 haemagglutinin-specific 
CD4+ IFNγ-positive or CD4+ IL2-positive responses, 
whereas H3 haemagglutinin-positive and influenza A 
matrix and nucleoprotein-specific responses were 
significantly increased from baseline (figure 4D; 
appendix p 14). By contrast, the 2017–18 LAIV induced 
significant pH1 haemagglutinin-specific CD4+ T-cells at 
day 21. Accordingly, a twofold or greater rise in pH1 
haemagglutinin-specific CD4+ T-cell responses was noted 
in more children given the 2017–18 LAIV than in those 
given the 2016–17 LAIV (50 of 109 [46%, 95% CI 36·3–55·7] 
vs 29 of 111 [26%, 18·2–35·3] for CD4+ IFNγ-positive 
responses; and 57 of 109 [52%, 42·5–61·9] vs 23 of 
111 [20·7%, 13·6–29·5] for CD4+ IL2-positive responses; 
figure 4C). A twofold or greater rise in CD4+ IFNγ-positive 
and/or CD4+ IL2-positive responses was recorded in 45 of 
111 children (41%, 95% CI 31·3–50·3) given the 2016–17 
LAIV and in 73 of 111 children (66%, 60·0–75·6) given 
the 2017–18 LAIV. B/Vic haemagglutinin-specific and 
influenza B matrix and nucleoprotein-specific CD4+ 
responses were also induced (appendix p 15). No 
significant change in the proportion of monofunctional or 
dual-functional CD4+ T-cell responses was seen after 
vaccination (appendix p 15). Influenza-specific mucosal 
IgA responses to pH1N1 did not differ between the 
2016–17 LAIV (16 of 117 children [14%, 95% CI 8·0–21·3]) 
and the 2017–18 LAIV (24 of 121 children [20%, 13·1–28·1]; 
p=0·27; figure 4E).
The effect of shedding on immunogenicity was 
investigated using H3N2 data (the largest sample of 
participants immunised with the same antigen and 
with T-cell data available). Seroconversion and T-cell 
responses were highest in children with shedding at both 
days 2 and 7 (appendix pp 16, 17). Multivariable logistic 
regression showed a significant effect of this prolonged 
shedding on the odds of seroconversion (odds ratio [OR] 
12·69, 95% CI 4·1–43·6; p<0·0001) and CD4+ T-cell 
responses (7·83, 2·99–23·5; p<0·0001; appendix pp 16, 
17). No such relation was seen with IgA responses 
(appendix pp 16–18). The odds of sero conversion were also 
reduced by higher baseline haem agglutinin inhibition titre 
(OR 0·11, 95% CI 0·04–0·27; p<0·0001)  and increased by 
induction of an H3 haem agglutinin-specific CD4+ 
IL2-positive response (2·42, 1·05–5·62; p=0·037). Similar 
findings were seen in B/Vic and NY15 pH1N1 datasets, 
albeit with smaller sample sizes (appendix pp 18–20).
Discussion
The findings of our study showed limited shedding, 
in vitro Cal09 replication, and low immunogenicity after 
administration of the 2016–17 LAIV in Gambian children, 
providing an explanation for the scant efficacy of this 
vaccine that was reported in a randomised controlled 
trial from neighbouring Senegal.4 After the switch to 
NY15, a significant increase in replication was seen, 
along with improved serum humoral and cellular 
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immunogenicity. No competitive inhibitory effect of 
enhanced pH1N1 replication was recorded with H3N2 or 
B/Vic replication or immunogenicity. Our data also 
showed that shedding for a longer duration is important 
for immunogenicity and that viral replicative fitness 
should be considered alongside antigenicity when 
selecting vaccine strains. Our findings represent the first 
reported LAIV immunogenicity data from African 
children and make a case for further studies of LAIV 
efficacy in Africa. They are also of relevance to the use of 
LAIV in other settings.
In a study of Ann Arbor-backbone LAIV, improved 
shedding and haemagglutinin inhibition seroconversion 
was reported with an updated A/Slovenia/2015 pH1N1 
strain.17 Parallel findings in two distinct cohorts of 
children—using two different LAIVs—provide strong 
support for Cal09 replicative fitness being culpable for 
the suboptimum pH1N1 LAIV effectiveness seen in 
recent years.2 Our finding that limited Cal09 shedding is 
unlikely to be attributable to pre-existing immunity 
further supports this result and argues against the notion 
that reduced LAIV effectiveness in the USA might have 
been due to repeated vaccination in previous years.18
In an earlier study using the Ann Arbor-backbone 
LAIV, pre-pandemic seasonal H1N1 shedding was 
found to be higher than for H3N2 or influenza B.19 Why 
pH1N1 Cal09 replication is impaired is uncertain. 
Haemagglutinin or neuraminidase residues must be 
the reason because the remaining six viral gene 
segments in LAIV are consistent between Cal09, NY15, 
and H3N2 strains. Differences in Cal09 haemagglutinin 
thermo stability, sialic acid receptor binding, or pH 
sensitivity are potential explanations for the lower 
replication noted.3 These properties are important for 
replication in the human upper respiratory tract. In 
particular, the pH of the upper respiratory tract in 
children might be lower than that of adults20 and have a 
deleterious effect on replication of viruses with labile 
haemagglutinin. The pH1N1 virus first crossed into 
human beings in 2009 and has subsequently circulated 
as a human seasonal virus. During this time, changes 
in haemagglutinin stability and receptor binding 
properties might have adapted the virus to replicate 
better in the human upper respiratory tract.21 Thus, the 
more recent haemagglutinin from A/Michigan/45/2015-
like viruses of 2015 could have conferred enhanced 
shedding to LAIV pH1N1 components.
We were able to mirror our findings in a primary 
human nasal epithelial cell model. These cells have a 
mildy acidic apical surface environment akin to that of 
the human upper respiratory tract. This strategy could be 
a practical method for assessing vaccine virus replication 
before strain choice. Because cell lines traditionally used 
to culture influenza viruses (eg, MDCK) might not truly 
reflect replication in the upper respiratory tract, these 
subtleties were previously underappreciated.22 Ultimately, 
a greater understanding of the viral genetic determinants 
of LAIV replicative fitness will be needed to select the 
best vaccine formulations.
Our study also emphasises the multifaceted nature of 
LAIV-induced immunity. Although seroresponse (the 
traditional correlate of protection after inactivated influ-
enza vaccine) is modest, LAIV also induces mucosal 
IgA and T-cell responses. In our cohort, T-cell responses 
were elicited in a larger proportion of children than 
were mucosal or serum antibodies, showing the 
importance of assessing cellular immunity in LAIV 
studies. Using the 2017–18 LAIV formulation, a CD4+ 
IFNγ-positive or CD4+ IL2-positive T-cell response was 
seen in 55–68% of children to the influenza antigens 
tested, with approximately 80% of children showing a 
response to haemagglutinin or matrix and nucleoprotein 
(appendix p 18). LAIV provides protection in the absence 
of humoral immunity23 and T-cell-mediated immunity is 
thought to have an important role.24
Unlike serum antibody and T-cell responses, we did 
not see an increase in mucosal IgA responses with NY15. 
This finding is in keeping with results reported after one 
dose of the updated Ann Arbor-backbone LAIV,17 
although a better response was seen after two doses. 
In a recent immuno genicity study of Nasovac-S in 
Bangladesh,25 unlike serum antibody, nasal pH1N1-
specific IgA was induced despite scant Cal09 shedding. 
Furthermore, by contrast to seroconversion and T-cell 
responses, we noted no association between shedding 
and IgA responses. Taken together, these data suggest 
the mechanisms and requirements for serum antibody 
and mucosal IgA induction by LAIV could be distinct.
Our study has several limitations. Although the associ-
ation between shedding and immunogenicity was a 
predefined exploratory objective in the larger randomised 
controlled trial our study was a part of, comparison of 
formulations containing Cal09 and NY15 was a post-hoc 
analysis made possible only because of the WHO-
recommended update to pH1N1 in the 2017–18 form-
ulation. Because we show an improvement in several 
shedding and immunogenicity endpoints with NY15, we 
are confident that our main conclusions are justified. 
Never theless, since our sample size was based on 
endpoints not reported here, the negative findings 
reported in some subanalyses should be interpreted with 
caution. Also, participants were vaccinated with one LAIV 
dose, in keeping with the prequalification license from 
WHO and the randomised controlled trials in Senegal4 
and Bangladesh.25 Our findings, therefore, might not be 
generalisable to children in high-income countries who 
receive booster doses and yearly influenza vaccination. 
We were also unable to confirm viral shedding with an 
LAIV-specific RT-PCR in all participants because of lower 
sensitivity compared with the haemagglutinin-specific 
RT-PCR, which is important to fully exclude interference 
from wild-type circulating strains. However, by doing the 
study outside of the peak influenza season,7 undertaking 
clinical review at enrolment, and doing baseline RT-PCR 
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screening for influenza virus, it is unlikely that our results 
were affected by wild-type influenza infections. Our 
shedding data at day 2 are also similar to those reported 
from Senegal using Nasovac-S (Cal09 19%, H3N2 48%, 
and influenza B 66%).4 Because we measured shedding 
with RT-PCR and not culture, we are unable to confirm to 
what degree shedding reflected viable viruses. Finally, an 
important unanswered question from our study is 
whether NY15 and related pH1N1 strains will result in 
improved LAIV effectiveness. Data from the 2017–18 UK 
season estimates the vaccine effectiveness (Ann Arbor-
backbone LAIV) to be 90·3% against pH1N1 in children 
aged 2–17 years.26 However, owing to low-level circulation 
of pH1N1, the precision around this estimate was low 
(95% CI 16·4–98·9). Our findings suggest improved 
effectiveness can indeed be expected with the updated 
LAIV and, if so, would support wider use of LAIV in the 
prevention of influenza.
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